Labcorp二季度收入增长5.8%并小幅上调全年指引

AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
Introduction & Market Context
Laboratory Corporation of America Holdings (NYSE:LH), known as Labcorp, released its second quarter 2026 supplemental financial information on July 30, 2026, showing accelerating revenue growth and expanding profit margins across both major business segments. The diagnostics and biopharma services company reported enterprise revenue of $3.73 billion, up 5.8% year-over-year, while raising its full-year guidance for both revenue and adjusted earnings per share.
The presentation comes as Labcorp shares trade near their 52-week high of $315.77, with the stock at $310.17 following the results. The company has now delivered five consecutive quarters of operating margin expansion, a trend that underscores improving operational efficiency alongside top-line growth.
Quarterly Performance Highlights
As shown in the following quarterly financial metrics table, Labcorp demonstrated consistent performance improvement across key indicators. Total Adjusted EBITDA reached $686.2 million in the second quarter of 2026, representing a significant increase from $627.8 million in the same period of 2025. The company’s leverage ratio, measured as total net debt to last twelve months Adjusted EBITDA, stood at 2.3x, reflecting a manageable debt position.
Revenue growth benefited from multiple factors, including organic expansion, acquisitions, and favorable foreign exchange movements. The following breakdown illustrates the foreign exchange impact on second quarter revenues across the enterprise. On a constant currency basis, enterprise revenue grew 5.4%, with foreign exchange contributing an additional 0.4 percentage point to reach the reported 5.8% growth rate.
For the first half of 2026, the foreign exchange tailwind was even more pronounced. Year-to-date enterprise revenues reached $7.27 billion, with constant currency growth of 4.9% enhanced by 0.9 percentage points from favorable exchange rates. The Biopharma Laboratory Services segment saw the most significant currency benefit, with foreign exchange contributing 3.6 percentage points to its 7.3% reported growth rate.
Segment Performance Analysis
The company’s revenue distribution remained heavily weighted toward its core Diagnostics Laboratories business, as illustrated in the following charts. Diagnostics accounted for 77.6% of total revenue, while Biopharma Laboratory Services contributed 22.4%. Geographically, the United States represented 83% of revenues, with international markets comprising the remaining 17%.
Diagnostics Laboratories generated $2.90 billion in second quarter revenue, up 5.5% year-over-year. The segment’s performance reflected balanced contributions from both volume and pricing, as detailed in the following analysis. Volume measured in requisitions grew 3.0%, while price and mix improvements added another 2.5 percentage points to revenue growth. This represents a moderation from the prior year’s stronger price/mix gains but demonstrates sustained momentum in both drivers.
The quarterly business segment data reveals important trends in the Diagnostics business mix. The routine versus esoteric test mix showed esoteric testing at 41.0% of revenue in the second quarter of 2026, up from 38.2% two years earlier. This shift toward higher-complexity testing typically supports better margins. The payer mix showed patient responsibility at 14.0% of revenue, the highest level in the tracked period, while client revenue declined to 28.9%.
Biopharma Services Momentum
Biopharma Laboratory Services delivered particularly strong results, with revenue of $836 million representing 6.5% year-over-year growth. The segment’s operational metrics demonstrate healthy underlying demand and business momentum, as shown in the following financial data. The quarterly book-to-bill ratio reached 1.14x, indicating new orders exceeded revenue by 14%. Net orders totaled $953.2 million, the highest quarterly level in the tracked period.
The segment’s backlog stood at $8.73 billion as of June 30, 2026, with approximately $2.75 billion expected to convert to revenue over the next twelve months. This provides significant visibility into future revenue streams and supports management’s confidence in the raised guidance. Central Laboratories revenue reached $609.3 million in the quarter, while Early Development Research Labs contributed $226.9 million.
Profitability and Margin Expansion
The presentation highlights Labcorp’s success in expanding profitability margins across the enterprise. As detailed in the following GAAP and non-GAAP income statement comparison, adjusted operating income reached $588.7 million in the second quarter of 2026, up from $531.6 million in the prior year period. This translated to an adjusted operating margin of 15.8%, representing a 70 basis point expansion from 15.1% a year earlier.
Adjusted diluted earnings per share grew 14.7% to $4.99 from $4.35 in the prior year quarter, outpacing revenue growth and demonstrating operating leverage. Net earnings attributable to Labcorp on a GAAP basis totaled $298.7 million, or $3.64 per diluted share, compared to $237.9 million or $2.84 per share in the second quarter of 2025.
The reconciliation of non-GAAP measures shows the key adjustments that bridge GAAP to adjusted results. The most significant items include $78.1 million in amortization of intangibles and other assets, $21.3 million in acquisition and disposition-related costs, and $11.7 million in LaunchPad business process improvement costs. These adjustments totaled $137.1 million pre-tax, with a net tax impact of $34.9 million.
Forward Outlook and Strategic Positioning
Management raised its full-year 2026 guidance across multiple metrics, reflecting increased confidence in the business trajectory. The updated outlook comparison shows enterprise revenue guidance increased to a range of $14.71 billion to $14.83 billion, representing 5.4% to 6.3% growth. This compares to previous guidance of $14.65 billion to $14.80 billion.
The adjusted earnings per share guidance range was lifted to $18.10 to $18.55, up from the prior range of $17.70 to $18.35. At the midpoint, this represents an increase of $0.30 per share, or approximately 1.7%. The Diagnostics Laboratories segment is now expected to grow 5.3% to 6.0%, while Biopharma Laboratory Services growth guidance was raised to 5.5% to 6.5% from a previous range of 3.8% to 5.4%.
The updated guidance incorporates favorable foreign exchange impacts of 0.4% for the enterprise and 1.5% for Biopharma Laboratory Services. Free cash flow guidance remained unchanged at $1.24 billion to $1.36 billion, suggesting management’s confidence in cash generation despite higher capital expenditure requirements.
Operational Efficiency Initiatives
The presentation documents ongoing investments in operational efficiency through the company’s LaunchPad initiative and other strategic programs. Non-GAAP adjustments include $24.7 million in LaunchPad costs for the first half of 2026, representing investments in system implementation, process consolidation, and business process improvements. These investments support the company’s margin expansion trajectory while positioning the business for sustainable long-term growth.
Depreciation totaled $97.5 million in the second quarter, while amortization of intangibles reached $78.1 million. The company’s capital allocation strategy balances investments in organic growth, strategic acquisitions, and shareholder returns. During the quarter, Labcorp maintained its leverage ratio at manageable levels while continuing to invest in technology and artificial intelligence tools to enhance diagnostic capabilities and operational efficiency.
The company’s strategic focus on specialty testing areas, including oncology, neurology, autoimmune disease, and women’s health, continues to drive above-market growth rates. Management indicated these specialty areas grew at double-digit rates in the first half of 2026, significantly outpacing the broader diagnostic testing market’s estimated 1% to 2% annual growth rate.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.